JPMorgan Chase & Co. Has $6.86 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

JPMorgan Chase & Co. grew its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 6.5% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 235,386 shares of the company’s stock after buying an additional 14,324 shares during the quarter. JPMorgan Chase & Co.’s holdings in Denali Therapeutics were worth $6,857,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of DNLI. FMR LLC raised its position in Denali Therapeutics by 3,234.3% in the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after purchasing an additional 7,596,508 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Denali Therapeutics by 63.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock valued at $109,223,000 after buying an additional 1,451,770 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Denali Therapeutics during the 2nd quarter worth about $24,454,000. Wellington Management Group LLP lifted its position in Denali Therapeutics by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock worth $312,491,000 after buying an additional 903,683 shares in the last quarter. Finally, Integral Health Asset Management LLC bought a new stake in Denali Therapeutics during the 2nd quarter worth about $7,546,000. Institutional investors own 92.92% of the company’s stock.

Insider Transactions at Denali Therapeutics

In other news, Director Vicki L. Sato sold 1,020 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the completion of the transaction, the director now directly owns 111,056 shares of the company’s stock, valued at $3,331,680. This trade represents a 0.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander O. Schuth sold 15,558 shares of the firm’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $29.91, for a total transaction of $465,339.78. Following the completion of the transaction, the insider now directly owns 178,066 shares of the company’s stock, valued at approximately $5,325,954.06. This trade represents a 8.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 104,518 shares of company stock valued at $2,576,982 over the last quarter. Corporate insiders own 7.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on DNLI shares. HC Wainwright reduced their target price on shares of Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. William Blair reaffirmed an “outperform” rating on shares of Denali Therapeutics in a report on Wednesday. Robert W. Baird started coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 target price for the company. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research report on Monday, December 16th. Finally, JPMorgan Chase & Co. decreased their price target on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, January 7th. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.91.

Denali Therapeutics Trading Up 14.7 %

Shares of DNLI opened at $21.50 on Thursday. The stock has a market cap of $3.09 billion, a P/E ratio of -7.79 and a beta of 1.39. The stock’s 50-day moving average price is $23.48 and its two-hundred day moving average price is $24.77. Denali Therapeutics Inc. has a 1 year low of $14.56 and a 1 year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the previous year, the company posted ($0.72) earnings per share. As a group, equities analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.